[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

APAC Osteoporosis Therapeutics Market to Reach USD 7.7 Bln in 2022, Says GBI Research in Its Topical Report Published at MarketPublishers.com

25 Aug 2016 • by Natalie Aster

LONDON – Characterised by low bone mass, consequent increase in fracture risk and microarchitectural deterioration of bone tissue, osteoporosis is known as the most common metabolic bone disease, which has become one of the major global public health problems. The rising number of elderly population worldwide and, thus, rising number of people suffering from osteoporosis will likely act as the key driver for revenue growth in the global osteoporosis therapeutics market.

At present, the osteoporosis therapeutics market is witnessing a gradual shift from a focus on antiresorptive therapeutic options to anabolic drug treatment. The market is set to follow an upward trend in the years to come, propelled by new product launches and novel drugs approvals.

Nowadays, osteoporosis therapeutics pipeline includes a broad range of therapeutic options including SERMs, bisphosphonates, RANKL inhibitors, calcitonins, a dual-action non-bisphosphonate (strontium ranelate) and PTH analogues. However, still there is considerable unmet need for effective antiresorptive therapies (offering increased compliance with minimum side effects) and for products able to improve bone formation.

In the previous year, the APAC osteoporosis therapeutics market was evaluated at around USD 4.5 billion. This regional market is expected to post a 7.8% CAGR in the next 6 years and in 2022 will likely reach the value of USD 7.7 billion.

In-demand research study “Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies” worked out by GBI Research provides a holistic all-encompassing analysis of the ongoing scenario in the APAC osteoporosis therapeutics market. It includes data on the disease pathogenesis, symptoms, diagnostics, prognosis and the current available treatment options. The report highlights the unmet needs existing in the regional market, analyses the osteoporosis pipeline, evaluates the potential of late-stage therapies, forecasts future market development trends and identifies emerging opportunities and challenges. Moreover, the market dynamics is thoroughly scrutinised here along with an insightful review of the major market growth drivers and barriers. Market forecasts through 2022 are also available in this research report. 

More comprehensive research studies by GBI Research are available at its page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest